116-69-8

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Bromophthalic acid is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its presence in the molecular structure of these compounds can influence their pharmacological properties, such as solubility, stability, and bioavailability, making it an essential component in drug development.
Used in Organic Compounds Synthesis:
As a versatile building block, 3-bromophthalic acid is employed in the synthesis of a wide range of organic compounds. Its reactivity with various reagents allows for the formation of new chemical entities with potential applications in various fields, including materials science, agrochemicals, and specialty chemicals.
Used in Dye and Pigment Production:
3-Bromophthalic acid is used in the production of dyes and pigments, where its unique chemical structure contributes to the color and stability of these products. Its incorporation into dye molecules can enhance their performance in various applications, such as textiles, plastics, and printing inks.
Used in Polymer and Plastics Manufacturing:
In the manufacturing of polymers and plastics, 3-bromophthalic acid serves as a crucial component that can influence the physical and chemical properties of the final products. Its presence in polymer formulations can improve characteristics such as thermal stability, mechanical strength, and resistance to environmental factors.
Used in Research and Development:
3-Bromophthalic acid is primarily used as an intermediate in organic synthesis and research. Its unique properties and reactivity make it a valuable tool for chemists to explore new reaction pathways, develop novel compounds, and advance the understanding of organic chemistry.

Upstream product

• 15115-60-3 4-bromo-2,3-dihydroinden-1-one 
• 576-23-8 2,3-dimethylbromobenzene 
• 23845-52-5 8-bromo-4-nitro-[1]naphthoic acid 
• 5328-76-7 1-bromo-5-nitronaphthalene 
• 116632-05-4 5-bromonaphthalen-2-ol 
• 76006-33-2 3-bromo-2-methylbenzoic acid 
• 99548-54-6 methyl 3-bromo-2-methylbenzoate 
• 64726-10-9 1,1,2,2-Tetrafluor-3-nitro-benzocyclobuten 
• 652-75-5 1,1,2,2-Tetrafluor-benzocyclobuten 
• 85-44-9 phthalic anhydride 
• 86-57-7 1-Nitronaphthalene 
• 526-75-0 2,3-Dimethylphenol 
• 603-11-2 3-nitrophthalic acid 
• 4766-33-0 5-amino-1-bromonaphthalene 

Downstream Products

• 19171-19-8 pomalidomide 
• 2093536-12-8 4-bromo-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 
• 105694-44-8 7-bromoisobenzofuran-1-(3H)-one 
• 102308-43-0 4-bromoisobenzofuran-1(3H)-one 
• 37418-88-5 3-hydroxyphthalic anhydride 
• 58749-33-0 dimethyl 3-bromophthalate 
• 82958-12-1 (3α,16α)-eburnamenine-14 carboxylic acid ester hydrochloride 
• 70478-63-6 6-bromophthalimide 

Relevant academic research and scientific papers

Preparation method of apremilast impurity

The invention discloses a preparation method of an apremilast impurity, and belongs to the technical field of apremilast impurity synthesis, the method comprises the following steps: taking 3-halogenated-2-methyl benzoic acid as a starting raw material to prepare an intermediate M1 through oxidation reaction, and performing dehydration condensation on the intermediate M1 to prepare an intermediate M2; taking 3, 4-dihydroxybenzonitrile as an initial raw material, carrying out an oxygen methylation reaction to prepare an intermediate M3, sequentially carrying out nucleophilic addition, a reduction reaction and alkaline hydrolysis on the intermediate M3 to prepare an intermediate M4, carrying out an amide exchange reaction on the intermediate M2 and the intermediate M4 to prepare an intermediate M5, and carrying out a coupling reaction and acid treatment on the intermediate M5 to obtain a target product. The method has the characteristics of reasonable synthetic route, easily available raw materials, simple and easy operation, high yield and high purity, and the prepared apremilast impurity can be used as a reference substance for qualitative and quantitative research of impurities in apremilast quality research, controls the content of related substances in bulk drugs, and ensures the quality of the bulk drugs.

FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The present invention also relates to compounds and methods useful for binding and modulating the activity of cereblon (CRBN), especially for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

HETEROCYCLIC DERIVATIVES

Compounds of the formula (I): Q1-Q2-Q3, in which Q1, Q2 and Q3 have the meanings indicated in Claim 1, degrade target proteins, and can be employed, inter alia, for the treatment of diseases such as cancer, multiple sclerosis, cardiovascular diseases, central nervous system injury and different forms of inflammation.

BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY

The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Enhanced fluorescence of phthalimide compounds induced by the incorporation of electron-donating alicyclic amino groups

Due to their high thermal and environmental stability, polyimides (PIs) are one of the most attractive candidates for novel highly fluorescent polymers, though photophysical studies of PIs are challenging owing to their poor solubility in common solvents. To overcome these problems, we have synthesized and examined a series of low molecular weight model imide compounds: substituted N-cyclohexylphthalimides with alicyclic amino groups at the 3 or 4-positions of the benzene rings (x-NHPIs). Their photophysical properties were systematically investigated by steady-state UV/Visible absorption, fluorescence, and time-resolved fluorescence techniques. In solution, unsubstituted N-cyclohexylphthalimide (NHPI) showed almost no emission, while x-NHPIs exhibited enhanced fluorescence emission depending on the solvent polarity. Analysis of the solvatochromism of the x-NHPIs via Lippert-Mataga plots indicated the generation of large dipole moments in the excited singlet states originating from the intramolecular charge-transfer (ICT) states. The significant difference in the fluorescence quantum yields (Φ) between the 3-substituted (3Pi and 3Pyr) and 4-substituted NHPIs (4Pi and 4Pyr) strongly suggests that the former form a twisted ICT (TICT) state, whereas the latter form a planar ICT (PICT) state when excited. 4-Substituted NHPIs also show high fluorescence yields in the crystalline state. A particularly large Φ value was obtained for the 4Pi crystal, which we explain by the large intermolecular distances and the arrangement of molecules minimizing intermolecular interactions as well as the small non-radiative deactivation rate. These facts clearly demonstrate that the introduction of an alicyclic amino group into NHPI at the 4-position enhances the fluorescence quantum yields significantly, which suggests a new pathway for the development of novel, highly fluorescent PIs.

NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A

The present invention relates to novel carboxamide compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating or controlling medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders

Synthesis and biological activity of n-butylphthalide derivatives

A series of n-butylphthalide derivatives were designed and synthesized. The in vitro activities of these compounds were evaluated by a resting tension of isolated rat thoracic aorta ring assay. Compounds 4g and 4i were found to be more active than n-butylphthalide.

Isoindole-imide compounds and compositions comprising and methods of using the same

This invention relates to isoindole-imide compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

On the regioselectivity of metal hydride reductions of 3-substituted phthalic anhydrides

A problem of 3-methoxyphthalide reduction by metal hydrides was reinvestigated. Various effects controlling selectivity of reductions in 3-substituted phthalides were studied, and a qualitative interpretation of the results is now proposed. Methods for obtaining enhanced yields of one or the other lactonic product were developed.